Hamilton Ben, Green Harry, Heerasing Neel, Hendy Peter, Moore Lucy, Chanchlani Neil, Walker Gareth, Bewshea Claire, Kennedy Nicholas A, Ahmad Tariq, Goodhand James
Exeter IBD Pharmacogenetics Research Group, University of Exeter, Exeter, UK.
Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, Devon, UK.
Frontline Gastroenterol. 2020 Jun 24;12(6):461-470. doi: 10.1136/flgastro-2019-101369. eCollection 2021.
We sought to define temporal changes in prevalence of inflammatory bowel disease (IBD) in East Devon, UK, in order to facilitate service planning over the next 5 years.
Multiple primary and secondary care databases were used to identify and verify cases. Point prevalence and incidence of IBD were reported in April 2017 and from 2008 to 2016, respectively. Future prevalence and healthcare activity requirements were estimated by linear regression.
Prevalence of ulcerative colitis (UC), Crohn's disease (CD) and inflammatory bowel disease unclassified (IBDU) were 479.72, 265.94 and 35.34 per 100 000 persons, respectively. In 2016, the incidence rates of UC, CD and IBDU were 15.4, 10.7 and 1.4 per 100 000 persons per year, respectively. There were no significant changes in the incidence of CD (p=0.49, R=0.26) or UC (p=0.80, R=0.10). IBD prevalence has increased by 39.9% (95% CI 28.2 to 53.7) in the last 10 years without differences in the rate of change between UC and CD. Overall, 27% of patients were managed in primary care, a quarter of whom were eligible but not receiving endoscopic surveillance. Outpatient clinics, MRI and biologic use, but not helpline calls, admissions, or surgeries increased over and above the change in IBD prevalence.
We report one of the highest prevalence and incidence rates of IBD from Northern Europe. Overall, IBD incidence is static, but prevalence is increasing. We estimate that 1% of our population will live with IBD between 2025 and 2030.
我们试图确定英国东德文郡炎症性肠病(IBD)患病率的时间变化情况,以便为未来5年的服务规划提供便利。
利用多个初级和二级医疗数据库来识别和核实病例。分别报告了2017年4月以及2008年至2016年IBD的时点患病率和发病率。通过线性回归估计未来患病率和医疗活动需求。
溃疡性结肠炎(UC)、克罗恩病(CD)和未分类的炎症性肠病(IBDU)的患病率分别为每10万人479.72例、265.94例和35.34例。2016年,UC、CD和IBDU的发病率分别为每年每10万人15.4例、10.7例和1.4例。CD(p = 0.49,R = 0.26)或UC(p = 0.80,R = 0.10)的发病率没有显著变化。在过去10年中,IBD患病率增加了39.9%(95%置信区间为28.2至53.7),UC和CD之间的变化率没有差异。总体而言,27%的患者在初级医疗中接受管理,其中四分之一符合条件但未接受内镜监测。门诊诊所、磁共振成像(MRI)和生物制剂的使用有所增加,但求助热线电话、住院或手术的增加幅度并未超过IBD患病率的变化。
我们报告了北欧IBD的最高患病率和发病率之一。总体而言,IBD发病率稳定,但患病率在上升。我们估计,在2025年至2030年期间,我们人口中有1%将患有IBD。